Shandong Sinobioway Biomedicine Co Ltd Cash Flow-to-Debt Ratio
Shandong Sinobioway Biomedicine Co Ltd cash flow-to-debt ratio. Shandong Sinobioway Biomedicine Co Ltd (002581) has a Cash Flow-to-Debt Ratio of -0.39x as of September 2025, meaning its operating cash flow of CN¥-86.58 Million could theoretically repay 0% of its total liabilities (CN¥221.51 Million) in one year. Check Shandong Sinobioway Biomedicine Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shandong Sinobioway Biomedicine Co Ltd (2007–2025)
Cash flow-to-debt ratio of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2025. Historical debt coverage capacity for Shandong Sinobioway Biomedicine Co Ltd across 19 annual periods. Check Shandong Sinobioway Biomedicine Co Ltd (002581) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shandong Sinobioway Biomedicine Co Ltd Cash Flow-to-Debt Ratio by Year (2007–2025)
Shandong Sinobioway Biomedicine Co Ltd cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Shandong Sinobioway Biomedicine Co Ltd. For the full cash flow conversion analysis, see 002581 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.14x | CN¥-253.73 Million | CN¥222.00 Million | ▼ -2930.8% |
| 2024 | -0.04x | CN¥-6.55 Million | CN¥173.61 Million | ▲ +83.1% |
| 2023 | -0.22x | CN¥-36.51 Million | CN¥163.41 Million | ▼ -59.7% |
| 2022 | -0.14x | CN¥-54.49 Million | CN¥389.46 Million | ▲ +12.8% |
| 2021 | -0.16x | CN¥-46.02 Million | CN¥286.76 Million | ▼ -320.5% |
| 2020 | 0.07x | CN¥18.51 Million | CN¥254.33 Million | ▲ +54.1% |
| 2019 | 0.05x | CN¥48.41 Million | CN¥1.03 Billion | ▼ -6.5% |
| 2018 | 0.05x | CN¥74.46 Million | CN¥1.47 Billion | ▼ -79.9% |
| 2017 | 0.25x | CN¥271.11 Million | CN¥1.08 Billion | ▼ -76.2% |
| 2016 | 1.06x | CN¥169.32 Million | CN¥160.16 Million | ▲ +108.7% |
| 2015 | 0.51x | CN¥137.73 Million | CN¥271.92 Million | ▼ -87.3% |
| 2014 | 3.99x | CN¥80.11 Million | CN¥20.08 Million | ▲ +70.3% |
| 2013 | 2.34x | CN¥83.13 Million | CN¥35.49 Million | ▼ -8.5% |
| 2012 | 2.56x | CN¥63.04 Million | CN¥24.62 Million | ▼ -38.4% |
| 2011 | 4.15x | CN¥74.43 Million | CN¥17.91 Million | ▲ +56.7% |
| 2010 | 2.65x | CN¥85.71 Million | CN¥32.34 Million | ▲ +72.8% |
| 2009 | 1.53x | CN¥54.06 Million | CN¥35.24 Million | ▼ -10.3% |
| 2008 | 1.71x | CN¥46.89 Million | CN¥27.41 Million | ▼ -20.8% |
| 2007 | 2.16x | CN¥25.07 Million | CN¥11.60 Million | — |